MAYNE PHARMA AND MITHRA ANNOUNCE
US LAUNCH OF HALOETTE®, A GENERIC VERSION OF
NUVARING®
13 January 2023, Adelaide, Australia and Liege, Belgium: Mayne Pharma Group
Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are
pleased to announce the launch of HALOETTE®
(etonogestrel and ethinyl estradiol) a
vaginal hormonal contraceptive ring into the US market.
HALOETTE® contraceptive is a generic version of NUVARING®
, a combined hormonal
contraceptive flexible ring indicated for the prevention of pregnancy. According to IQVIA,
NUVARING® US brand and generic sales were approximately USD 564 million for the
12 months ended November 2022.
Under the terms of the long-term license and supply agreement, Mayne Pharma will pay
Mithra a milestone of EUR 1.6 million.
Mayne Pharma’s CEO Mr Shawn O’Brien said: “We are pleased to announce the
launch of HALOETTE®
in the US. This is another example of our commitment to providing
women with more contraceptive choice. Mayne Pharma continues to expand its women’s
health portfolio with the recent launch of NEXTSTELLIS®
(estetrol/drospirenone) in the
US and Australia, and our new license agreement for ANNOVERA®, IMVEXXY® and
BIJUVA® from TherapeuticsMD.”
Mithra’s CEO Mr Leon Van Rompay said: “We are pleased to start the year with the
commercial launch of our affordable contraceptive alternative in the US, the world's
largest pharmaceutical market. This key milestone has been reached thanks to the
support of our Mithra CDMO, highlighting its unique expertise in developing and
manufacturing complex pharmaceutical devices.”